Crestor approved for cardiovascular risk reduction - MPR
Links shared publicly online about this topic.
- 1,394total visits
Crestor approved for cardiovascular risk reduction - MPR
empr.com —
View full resource at empr.com
Tags: Cholesterol Medication, Stroke, Mineral, Calcium, Supplement, FDA, Crestor, AstraZeneca
Most Recently Shared on February 9, 2010 at 4:22 pm By:
MPR News: Crestor approved for cardiovascular risk reduction: The FDA has approved Crestor (rosuvastatin calcium t... http://bit.ly/9BEvsW
AstraZeneca's CRESTOR: Health Canada approves new indication
news-medical.net — “AstraZeneca announced today that Health Canada has approved CRESTOR (rosuvastatin calcium) to reduce the risk of nonfatal myocardial infarction (heart attack), nonfatal stroke, and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease.” View full resource at news-medical.net
Most Recently Shared on March 17, 2010 at 2:22 pm By:
Stroke News: AstraZeneca's CRESTOR: Health Canada approves new indication: AstraZeneca announced today that Heal... http://twurl.nl/7ql3ku
FDA Approves New Indication For Crestor
medicalnewstoday.com — “On Feb. 8 the U.S. Food and Drug Administration approved the cholesterol-lowering medication Crestor (rosuvastatin) for some patients who are at increased risk of heart disease but have not been d” View full resource at medicalnewstoday.com
Most Recently Shared on February 10, 2010 at 5:07 pm By:
MNT Cholesterol News Health News
FDA Approves New Indication For Crestor http://mnt.to/3xsr #cholesterol
US FDA Approves New Indication For CRESTOR® (Rosuvastatin Calcium)
medicalnewstoday.com — “AstraZeneca (NYSE: AZN) announced that the US Food and Drug Administration (FDA) has approved CRESTOR® (rosuvastatin calcium) to reduce the risk of stroke, myocardial infarction (heart attack)” View full resource at medicalnewstoday.com
Most Recently Shared on February 10, 2010 at 12:37 pm By:
US FDA Approves New Indication For CRESTOR® (rosuvastatin Calcium) AstraZeneca (NYSE: AZN) announced that the US Foo.. http://bit.ly/a4TRFd
European Commission approves MICARDIS medication for CV protection
news-medical.net — “MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.” View full resource at news-medical.net
Most Recently Shared on November 27, 2009 at 12:40 pm By:
Stroke News: European Commission approves MICARDIS medication for CV protection: MICARDIS® is the first treatmen... http://twurl.nl/fa5ea3
FDA Approves MICARDIS(R) As The First Treatment In Its Class To Reduce The Risk Of Heart Attack, Stroke, Or Death From Cardiovascular Causes...
medicalnewstoday.com — “Boehringer ingelheim announced that the us food and drug administration (fda) has approved a new indication for micardis® (telmisartan) for the reduction of the risk of myocardial infarction (” View full resource at medicalnewstoday.com
Most Recently Shared on October 21, 2009 at 11:22 am By:
MedicalNewsToday: FDA Approves MICARDIS(R) As The First Treatment In Its Class To Reduce: http://bit.ly/2Am5jB Full http://bit.ly/423dI5
FDA approves Boehringer Ingelheim's MICARDIS for the reduction of risk of heart attack
news-medical.net — “Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved a new indication for MICARDIS® (telmisartan) for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors. MICARDIS® is the first treatment in its class to be approved for this indication.” View full resource at news-medical.net
Most Recently Shared on October 19, 2009 at 5:06 pm By:
Stroke News: FDA approves Boehringer Ingelheim's MICARDIS for the reduction of risk of heart attack:.. http://twurl.nl/n1anwp
Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg
news-medical.net — “Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) in” View full resource at news-medical.net
Most Recently Shared on October 19, 2009 at 5:06 pm By:
Stroke News: Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Ta.. http://twurl.nl/oswp1h
FDA Approves New Use for Micardis(R) in Cardiovascular Risk Reduction and Twynsta(R) as New Combination Treatment for High Blood Pressure | Reuters
reuters.com — “FDA Approves New Use for Micardis(R) in Cardiovascular Risk Reduction and Twynsta(R) as New Combination Treatment for High Blood Pressure MICARDIS is First ARB Indicated to Reduce Risk of Cardiovascular” View full resource at reuters.com
Most Recently Shared on October 19, 2009 at 1:59 pm By:
Tammi Jacobs Health Professional
FDA Approves New Use for Micardis(R) in Cardiovascular Risk Reduction and ... http://bit.ly/2yT1Qw
Advertisement
